Non-valvular AF stroke risk — ESC 2023 / ACC/AHA 2023
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Assessment of thromboembolic stroke risk in adults with non-valvular atrial fibrillation (paroxysmal, persistent, or permanent).
Decision support for initiating or withholding oral anticoagulation (OAC) therapy.
Identifying "truly low-risk" patients (Score 0 in males, Score 1 in females) who derive no net benefit from OAC.
Recalculation at each clinical encounter, as newly acquired risk factors change management.
Endorsed By
Recommended by the ESC 2020 AF Guidelines (Class I, Level A), the 2023 ACC/AHA/ACCP/HRS AF Guideline, and the European Heart Rhythm Association (EHRA). It is the global standard for AF stroke stratification.
When NOT to Use
Valvular AF (moderate-to-severe mitral stenosis or mechanical heart valve): These patients require warfarin (target INR 2–3 or 2.5–3.5) regardless of score — DOACs are contraindicated.
Hypertrophic Cardiomyopathy (HCM): HCM-related AF carries high inherent stroke risk; anticoagulate without scoring.
Cardiac Amyloidosis with AF: Consider anticoagulation even at low scores — CHA₂DS₂-VASc may underestimate risk.
Pregnancy: Anticoagulant choice (LMWH preferred) is independent of this score.
Definition of "Non-Valvular" AF
The ESC 2020 guideline redefines "non-valvular" to exclude only moderate-to-severe rheumatic mitral stenosis and prosthetic mechanical heart valves. Bioprosthetic valves, mitral valve repair, aortic stenosis, and mitral regurgitation do NOT exclude a patient from CHA₂DS₂-VASc stratification and DOAC use.
Section 2
Formula & Logic
Scoring Variables
| C — Congestive Heart Failure | Symptomatic HF or reduced LVEF ≤ 40%, even if currently compensated (1 pt) |
| H — Hypertension | Resting BP > 140/90 mmHg on ≥ 2 readings, or on antihypertensive treatment (1 pt) |
| A₂ — Age ≥ 75 years | Strongest age-related predictor; carries double weight (2 pts) |
| D — Diabetes Mellitus | Fasting glucose > 126 mg/dL, HbA1c ≥ 6.5%, or on glucose-lowering therapy (1 pt) |
| S₂ — Prior Stroke/TIA/TE | History of ischaemic stroke, transient ischaemic attack, or systemic thromboembolism; highest single weight (2 pts) |
| V — Vascular Disease | Prior myocardial infarction, peripheral arterial disease, or complex aortic plaque on imaging (1 pt) |
| A — Age 65–74 years | Mutually exclusive with A₂; applies only if age is 65–74 (1 pt) |
| Sc — Sex Category (Female) | Risk modifier — adds 1 pt but does not constitute an independent indication for OAC when it is the only point (1 pt) |
Annual Stroke Risk by Score (ESC 2020)
| Score 0 | ~0% — Negligible risk |
| Score 1 | ~1.3% — Low |
| Score 2 | ~2.2% — Low-Moderate |
| Score 3 | ~3.2% — Moderate |
| Score 4 | ~4.0% — Moderate-High |
| Score 5 | ~6.7% — High |
| Score 6 | ~9.8% — High |
| Score 7 | ~11.2% — Very High |
| Score 8 | ~12.5% — Very High |
| Score 9 | ~15.2% — Very High |
Maximum Score
The maximum possible score is 9 (both A₂ and S₂ score 2 points each; all other variables score 1 point each). A patient cannot score both A (age 65–74) and A₂ (age ≥75) simultaneously — these are mutually exclusive brackets.
Section 3
Pearls/Pitfalls
High-Impact Insights
A score of 0 (males) confers approximately 0% annual stroke risk — these patients derive no net clinical benefit from anticoagulation, which itself carries bleeding risk.
The female sex category (Sc) is a risk modifier, not an independent risk factor. A female with no other risk factors (Score = 1 from sex alone) should NOT be anticoagulated per current guidelines.
Prior stroke/TIA (S₂) is the single most powerful predictor and alone justifies anticoagulation regardless of other factors.
CHA₂DS₂-VASc outperforms the older CHADS₂ score by reclassifying ~15% of "intermediate-risk" CHADS₂ patients into truly low or high categories.
Newly diagnosed AF at first presentation: calculate the score immediately and initiate OAC before cardioversion if the score warrants it.
Pitfalls & Nuances
CKD is NOT a variable despite being an independent risk factor for both stroke and bleeding — CKD patients may be systematically underscored.
Obstructive sleep apnea (OSA), obesity, and alcohol excess are not scored but substantially increase AF burden and stroke risk.
AF episode duration matters for device-detected sub-clinical AF (AHRE) — consult ARTESIA and NOAH-AFNET 6 trial data for guidance in this evolving area.
Score recalculation is recommended at each review — a patient who was low-risk at age 64 crosses into the Sc/A band at 65 and the A₂ band at 75.
Do not conflate CHA₂DS₂-VASc score with bleeding risk — always pair with HAS-BLED or ORBIT for a complete risk-benefit assessment.
Virchow's Triad in the AF Context
The score variables map elegantly to Virchow's Triad: blood stasis(HF reduces left atrial emptying velocity), endothelial dysfunction(HTN and DM damage the atrial endocardium), and hypercoagulability(ageing, vascular disease, and prior thromboembolism all activate pro- coagulant pathways).The left atrial appendage(LAA) is the thrombus source in > 90 % of AF - related strokes.
Paroxysmal vs. Permanent AF
Stroke risk is similar across all AF types (paroxysmal, persistent, permanent, long-standing persistent). Do not withhold anticoagulation from paroxysmal AF patients who meet the threshold — the score applies equally regardless of AF pattern.
Section 4
Next Steps
Management Thresholds (ESC 2020 / ACC 2023)
01
Score 0 (males) / Score 1 (females, sex point only): Omit anticoagulation. Reassess at next encounter.
02
Score 1 (males) / Score 2 (females): "Consider" OAC (Class IIa). Engage in shared decision-making; weigh stroke vs. bleeding risk using HAS-BLED. Patient preference is pivotal.
03
Score ≥ 2 (males) / ≥ 3 (females): Oral anticoagulation is strongly recommended (Class I, Level A). Prefer DOACs over VKA in DOAC-eligible patients.
DOAC vs. Warfarin Selection
DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin for non-valvular AF: superior or non-inferior stroke prevention, lower intracranial hemorrhage rates, and no routine INR monitoring. Warfarin remains required for mechanical heart valves and moderate-to-severe mitral stenosis.
Assessing Bleeding Risk (HAS-BLED)
A high HAS-BLED score (≥ 3) signals correctable bleeding risk factors — not a contraindication to OAC. Address modifiable risks: uncontrolled hypertension, labile INR, excess alcohol, interacting drugs (NSAIDs, antiplatelets), and falls risk. High bleeding risk alone should not override a clear indication for anticoagulation.
Left Atrial Appendage Occlusion (LAAO)
LAAO devices (e.g., Watchman FLX) may be considered for patients with high CHA₂DS₂-VASc scores who have absolute contraindications to long-term anticoagulation (e.g., recurrent life-threatening hemorrhage despite risk factor correction). This is a Class IIb recommendation and does not replace OAC as first-line.
Complementary Calculators
HAS-BLED Bleeding Risk Score
ORBIT Bleeding Risk Score
ABC-AF Stroke Risk Score
ABC-AF Bleeding Risk Score
HEMORR₂HAGES Score
CHADS₂ Score
Cockcroft-Gault CrCl (for DOAC dosing)
eGFR (CKD-EPI 2021)
EHRA Symptom Scale
Section 5
Evidence Appraisal
Primary Derivation
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach.
Lip GY et al. • Chest.. 2010;n = 1,084 (Euro Heart Survey). Introduced the Vascular Disease and age 65–74 variables. Demonstrated superiority to CHADS₂ at identifying truly low-risk patients (c-statistic 0.606 vs 0.553).
Large-Scale Validation
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
Friberg L et al. • Eur Heart J.. 2012;n = 182,678 (population-wide registry). Confirmed superior C-statistic of CHA₂DS₂-VASc (0.67) vs CHADS₂ (0.66) for stroke prediction. Particularly strong at identifying those who can safely avoid anticoagulation.
Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation.
Van den Ham HA et al. • J Am Coll Cardiol.. 2015;n = 39,400 (UK CPRD). CHA₂DS₂-VASc was superior to both CHADS₂ and ATRIA in predicting first ischaemic stroke across multiple demographic subgroups.
Key Guideline Endorsements
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation.
Hindricks G et al. • Eur Heart J.. 2021;Class I recommendation for CHA₂DS₂-VASc. Reaffirmed female sex as modifier (not independent risk factor). Endorsed DOACs as preferred OAC.
2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation.
Joglar JA et al. • J Am Coll Cardiol.. 2024;Updated US guideline affirming CHA₂DS₂-VASc with specific thresholds per sex, DOACs preferred, and expanded guidance on LAAO devices and device-detected AF.
Section 6
Literature
From CHADS₂ to CHA₂DS₂-VASc
The original CHADS₂ score (2001) classified up to 60% of AF patients into an "intermediate risk" zone — a clinically unhelpful gray area. In 2010, Gregory Lip and colleagues refined the model using the Euro Heart Survey data, adding three new variables (vascular disease, age 65–74, and female sex) to better discriminate truly low-risk from moderate- and high-risk patients. The resulting CHA₂DS₂-VASc score was rapidly adopted globally and replaced CHADS₂ in all major guidelines by 2012.
Professor Gregory Lip
Professor Gregory Y.H. Lip, University of Liverpool and Aalborg University, is one of the world's most cited cardiovascular clinician-scientists. His work has shifted AF management from a rhythm-focused to a holistic stroke-prevention paradigm. He has chaired multiple ESC working groups and contributed to over 1,500 peer-reviewed publications. The CHA₂DS₂-VASc score is arguably the most clinically impactful risk score in cardiology.
Global Adoption Timeline
01
2001 — CHADS₂ score published (Gage BF et al., JAMA). Became the first widely used AF stroke tool.
02
2006 — ACC/AHA/ESC Guidelines incorporate CHADS₂ for anticoagulation decisions.
03
2010 — CHA₂DS₂-VASc introduced (Lip GY et al., Chest). Adds vascular disease, age 65–74, female sex.
04
2012 — ESC AF Guidelines replace CHADS₂ with CHA₂DS₂-VASc as primary stratification tool.
05
2014 — ACC/AHA adopt CHA₂DS₂-VASc in US AF guidelines.
06
2016 — 2016 ESC AF Guidelines refine sex-category threshold (female alone = no OAC).
07
2020 — ESC 2020 AF Guidelines finalize current thresholds; DOACs definitively preferred over warfarin.
08
2023 — ACC/AHA update with device-detected AF guidance and expanded LAAO indications.
Last Comprehensive Review: 2026